Hims & Hers Health Sees Unusually High Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of some unusual options trading on Monday. Stock traders purchased 67,660 call options on the company. This is an increase of approximately 52% compared to the average daily volume of 44,492 call options.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of research analyst reports. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Trading Up 23.9 %

HIMS stock opened at $31.39 on Tuesday. Hims & Hers Health has a 1-year low of $8.09 and a 1-year high of $31.40. The firm has a market cap of $6.86 billion, a PE ratio of 71.34 and a beta of 1.06. The business’s 50-day moving average price is $20.85 and its two-hundred day moving average price is $19.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the business posted ($0.04) earnings per share. On average, analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares of the company’s stock, valued at $2,960,446.53. This represents a 64.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $13,258,692.64. The trade was a 8.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,049,183 shares of company stock valued at $21,395,632. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. Wellington Management Group LLP boosted its stake in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Geode Capital Management LLC grew its holdings in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after buying an additional 328,142 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.